Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Efgartigimod shows promise in treatment-resistant myasthenia gravis
Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.
Efgartigimod shows promise in treatment-resistant myasthenia gravis
09 Jul 2024
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
Treatment with anti-CD20 monoclonal antibodies appears to be a viable option for patients with relapsing-remitting multiple sclerosis (RRMS) who have uncontrolled disease following the use of alemtuzumab therapy, suggests a study presented at EAN 2024.
Anti-CD20 show promise in multiple sclerosis after alemtuzumab
08 Jul 2024
Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC
Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.